[FOR PUBLIC CONSULTATION] DRAFT Philippines Guidance Document for the Use of Real-World Evidence in Clinical Assessment of Health Technologies

Published on 11 December 2024 This is to update all our stakeholders that the Health Technology Assessment (HTA) Division has completed the Philippine Guidance Document on the Use of Real-World Evidence in Clinical Assessment of Health Technologies [DRAFT]. This is part of our ongoing efforts to develop specific HTA Method Guides across different health technologies. continue reading : [FOR PUBLIC CONSULTATION] DRAFT Philippines Guidance Document for the Use of Real-World Evidence in Clinical Assessment of Health Technologies

Omnibus HTA Tracker

Date of Last Update: 25 November 2024 HTA Philippines shares with its stakeholders the 🗃️Omnibus HTA Tracker, a comprehensive and up-to-date file that consolidates all completed, and currently being undertaken assessments by the HTA Council and the HTA Division. This serves as a temporary resource while we work on updating the HTA website. The tracker continue reading : Omnibus HTA Tracker

[FOR PUBLIC CONSULTATION] HTA Council Preliminary Recommendation on Dapivirine Vaginal Ring, Donepezil Hydrochloride, Tenofovir/Lamivudine/Dolutegravir and Tenofovir + Lamivudine in combination with Dolutegravir

Published on 21 October 2024 As of 21 October 2024, the Health Technology Assessment (HTA) Council hereby makes public its preliminary recommendations on the possible inclusion in the Philippine National Formulary (PNF) and thus the government financing of the following health technologies, for stakeholder feedback/comments: These health technologies were reviewed against national clinical practice guidelines continue reading : [FOR PUBLIC CONSULTATION] HTA Council Preliminary Recommendation on Dapivirine Vaginal Ring, Donepezil Hydrochloride, Tenofovir/Lamivudine/Dolutegravir and Tenofovir + Lamivudine in combination with Dolutegravir